Non Hodgkin Lymphoma Clinical Trial

Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma

Summary

This is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib combined with rituximab in previously untreated subjects with Follicular Lymphoma (FL).

View Full Description

Full Description

This is an open-label, Phase 2 study designed to assess the efficacy and safety of ibrutinib combined with rituximab in previously untreated subjects with FL.

There are two study treatment arms.

Subjects enrolled into main study treatment arm will receive ibrutinib continuously until disease progression or unacceptable toxicity. In addition, subjects will receive rituximab once weekly for four doses for the first four weeks of study treatment.

Subjects enrolled into the exploratory study treatment arm will receive ibrutinib continuously as a single agent for the first eight weeks, then ibrutinib concurrently with rituximab once weekly for four doses. After the rituximab treatment, subjects will receive ibrutinib continuously until disease progression or unacceptable toxicity.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion criteria:

Histologically documented FL (Grade 1, 2 and 3A)
Not previously treated with prior anti-cancer therapy for FL
Stage II, III or IV disease
At least one measurable lesion ≥ 2 cm in longest diameter by CT and/or MRI scan
Men and women ≥ 18 years of age
Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

Key Exclusion criteria:

Medically apparent central nervous system lymphoma or leptomeningeal disease
FL with evidence of large cell transformation
Any prior history of other hematologic malignancy besides FL or myelodysplasia

History of other malignancies, except

Malignancy treated with curative intent and with no known active disease present for ≥5 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.
Adequately treated non-melanoma skin cancer or lentigomaligna without evidence of disease.
Adequately treated carcinoma in situ without evidence of disease.
Currently active, clinically significant cardiovascular disease or myocardial infarction within 6 months of screening
Known anaphylaxis or Immunoglobulin E (IgE)-mediated hypersensitivity to murine proteins or to any component of rituximab (Rituxan®)
Requires anti-coagulation with warfarin or a vitamin K antagonist.
Requires treatment with strong cytochrome P450 (CYP) 3A inhibitors.
Known bleeding diathesis or hemophilia

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

80

Study ID:

NCT01980654

Recruitment Status:

Completed

Sponsor:

Pharmacyclics LLC.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

Providence Saint Joseph Medical Center
Burbank California, 91505, United States
City of Hope
Duarte California, 91010, United States
UCLA Medical Center
Los Angeles California, 90095, United States
Stanford University, Stanford Care Center
Stanford California, 94305, United States
Southeastern Regional Medical Center
Newnan Georgia, 30265, United States
Community Health Network Community Regional Cancer Center North
Indianapolis Indiana, 46256, United States
Comprehensive Cancer Centers of Nevada
Henderson Nevada, 89074, United States
Memorial Sloan-Kettering Cancer Center
New York New York, 10065, United States
Weill Cornell Medical College New York-Presbyterian Hospital
New York New York, 10065, United States
Mid-Ohio Oncology/ Hematology Inc
Columbus Ohio, 43219, United States
Tennessee Oncology, PLLC The Sarah Cannon Research Institute
Nashville Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 2

Estimated Enrollment:

80

Study ID:

NCT01980654

Recruitment Status:

Completed

Sponsor:


Pharmacyclics LLC.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider